Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).

VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

Share this video  

COMy Virtual 2020 | Key game-changers in multiple myeloma

Kenneth Anderson • 4 May 2020
COMy Virtual 2020
Multiple Myeloma Antibodies Belantamab mafodotin Bortezomib CAR-T Daratumumab Isatuximab Venetoclax

Kenneth Anderson, MD, Dana-Farber Cancer Institute, Boston, MA, discusses the most exciting developments in the treatment of multiple myeloma (MM). Specifically, targeted therapies and immunotherapy. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Kenneth Anderson

Defining high-risk myeloma in the era of immune therapies: progress made, unmet needs & more
13:45
Defining high-risk myeloma in the era of immune therapies: progress made, unmet needs & more
Kenneth Anderson • 24 Oct 2025
Defining high-risk multiple myeloma: recent advances in the field & future considerations
Defining high-risk multiple myeloma: recent advances in the field & future considerations
Kenneth Anderson • 4 Nov 2024
Collaboration in the myeloma community
1:27
Collaboration in the myeloma community
Kenneth Anderson • 14 May 2022
The future of myeloma treatment and the possibility of cure
4:04
The future of myeloma treatment and the possibility of cure
Kenneth Anderson • 14 May 2022

Related Videos

Updated results from the iMMagine-1 trial of anito-cel in R/R multiple myeloma
4:32
Updated results from the iMMagine-1 trial of anito-cel in R/R multiple myeloma
Kenneth Anderson • 18 Dec 2025
Investigating AZD0120, a dual-targeting CAR-T product, in R/R myeloma: DURGA-1 preliminary results
3:36
Investigating AZD0120, a dual-targeting CAR-T product, in R/R myeloma: DURGA-1 preliminary results
Kenneth Anderson • 7 Dec 2025
A Phase II trial investigating IberKDd in R/R multiple myeloma: the ReKInDLE study
3:11
A Phase II trial investigating IberKDd in R/R multiple myeloma: the ReKInDLE study
Kenneth Anderson • 7 Dec 2025
Remote therapeutic monitoring reduces infection-related hospitalizations in hematologic cancers
4:04
Remote therapeutic monitoring reduces infection-related hospitalizations in hematologic cancers
Kenneth Anderson • 15 Dec 2025
The content of VJHemOnc is intended for healthcare professionals